Free preview. Sign up free to see the team, full portfolio, ownership chain, and shareholding history.
Rtw Biotech Opportunities Operating Ltd investment portfolio
Rtw Biotech Opportunities Operating Ltd has made numerous investments in companies such as Artios Pharma, Ottimo Pharma, and Reneuron Group within the Healthcare & Life Sciences sector.
unknown
Portfolio
3
Team
0
Portfolio (3)
| Company | Sector | City | Source | Last confirmed on |
|---|---|---|---|---|
| Artios Pharma Limited Artios Pharma Limited develops DNA‑damage‑response‑based cancer therapeutics. Its pipeline includes the ATR inhibitor alnodesertib and the Polθ inhibitor ART6043, targeting hard‑to‑treat solid tumours. | Healthcare & Life Sciences | Cambridge | Confirmed | 2025-12-28 |
| Ottimo Pharma Limited Ottimo Pharma develops bifunctional, dual‑paratopic antibodies that simultaneously target PD‑1 and VEGFR2 to treat cancer, aiming to extend the lives of patients with malignancies. It is a clinical‑stage biotechnology company focused on advancing these novel immuno‑oncology therapeutics through clinical development. | Healthcare & Life Sciences | Sandwich | Confirmed | 2026-01-21 |
Shareholding changes (2)
Sign up free to see when this investor has bought or sold shares.
Sign up free